ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO418

Survival of Patients with CKD Stages 1-5 in Iceland

Session Information

Category: CKD (Non-Dialysis)

  • 2101 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention


  • Jonsson, Arnar Jan, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland
  • Lund, Sigrún Helga, deCODE genetics, Reykjavík, Iceland
  • Palsson, Runolfur, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland
  • Indridason, Olafur S., Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland

Studies on survival of patients with chronic kidney disease (CKD) employing the KDIGO definition and classification system with repeated serum creatinine (SCr) and proteinuria measurements are scarce. The purpose of this study was to estimate hazard ratio (HR) for death in patients with CKD stages 1-5 in Iceland.


In this retrospective study, we obtained all SCr values and urine protein measurements from every clinical laboratory in Iceland in 2008-2016. Clinical information, including ICD-10 diagnosis codes, was retrieved from nationwide electronic medical records. Estimated glomerular filtration rate (eGFR) was calculated from SCr using the CKD-EPI equation. CKD was defined as presence of kidney damage, either ICD-10 diagnosis codes indicating kidney disease or proteinuria, or as eGFR <60 mL/min/1.73 m2 for ≥3 months. Cox regression was used for survival analysis with CKD stage as a time-dependent variable and adjustments for age at study entry, sex, number of SCr measurements, initial eGFR, multiple co-morbid conditions and by CKD detection criteria, i.e. proteinuria, kidney specific diagnosis or reduced eGFR, either by a single criterion or various combinations.


We obtained 2,120,232 SCr values for 218,437 individuals and information on proteinuria for 84,364 individuals. A total of 4972 had persistent proteinuria, 5286 had kidney disease diagnoses and 20131 had eGFR <60 mL/min/1.73 m2 . The median age was 46 (range, 18-107) years and 47% were men. Compared with individuals without CKD, the hazard ratios (95%CI) for patient survival were 10.39 (7.62-14.17), 3.92 (3.18-4.85), 1.43 (1.31-1.56), 2.00 (1.83-2.20), 3.15 (2.78-3.57) and 11.18 (8.96-13.95) for CKD stages 1, 2, 3a,3b, 4 and 5, respectively.


This nationwide study on survival of patients with CKD, incorporating kidney disease diagnoses and numerous urine protein and SCr values over time, suggests increased risk of death for all CKD stages. While this finding supports current criteria for definition of CKD, a more detailed analysis of the influence age is needed.